REG - Alliance Pharma PLC - New Chair Appointment

Alliance PharmaAnnouncement

05/02/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240205:nRSE9438Ba&default-theme=true

RNS Number : 9438B  Alliance Pharma PLC  05 February 2024

 For immediate release  5 February 2024

 

 

ALLIANCE PHARMA PLC

("Alliance", "Company" or the "Group")

 

New Chair Appointment

 

Alliance Pharma plc (AIM: APH), the international healthcare group, announces
its plans for Board evolution.

Alliance has transitioned from a Prescription Medicines business to a fast
growth Consumer Healthcare company over recent years, with Consumer Healthcare
revenues representing 75% of Group revenues in 2023. Over the last five years,
Jo LeCouilliard has been instrumental in driving this transition, first as a
Non-Executive Director and, more recently, as Chair. Under her leadership, the
Company has strengthened the Board, appointing two new directors with Consumer
experience, particularly in the APAC region. Jo and the Board feel that it is
now appropriate for her to step down from the Board and to appoint a new
Chair, with strong international Consumer Healthcare experience, to lead the
Company through its next strategic phase, focusing on organic growth through
marketing and innovation.

The Board is pleased to announce that Camillo Pane will be appointed to the
Board and assume the role of Chair on 19 February 2024 following a handover
period from Jo. Camillo has over thirty years' experience in US, European and
Asian public, multinational Consumer companies. During his career, Camillo has
held a number of senior positions at Reckitt Benckiser where he spent almost
20 years across both Global and Regional roles, including Senior Vice
President and Global Category Officer for Consumer Health, before moving to
Coty Inc, one of the largest beauty companies in the world, where, as CEO, he
led the merger with Procter & Gamble Specialty Beauty. Most recently, he
was Group CEO of Health & Happiness Group, a global Health and Nutrition
company listed on the Hong Kong Stock Exchange with revenues of around $2bn.

Richard Jones, Senior Independent Director of Alliance, commented:

"On behalf of the Alliance Board and the Company I would like to thank Jo for
her significant contribution to Alliance over the past five years and wish her
well for the future. We look forward to Camillo joining the Board as Chair and
harnessing his wide-ranging consumer healthcare experience to further enhance
and develop our Group strategy. In the meantime, the Board remains focused on
creating value for our shareholders by investing in growth whilst carefully
managing our cost base."

In accordance with Schedule 2 (g) of the AIM Rules for Companies, Camillo Pane
(aged 53 years) holds/has held the following directorships/partnerships in the
last five years:

 

 Current directorships/partnerships       Previous directorships/partnerships (last five years)
 ·      VCP & Partners Limited            ·      Ocean Labs Beauty Ltd

 ·      LSG Hydra Limited                 ·      Loum Holdings Ltd

 ·      Passione Beauty s.p.a.            ·      Present Life Ltd

                                          ·      Kadenwood Inc

Camillo Pane currently holds no ordinary shares in the Company.

 

There are no further disclosures to made be under Schedule 2(g) of the AIM
Rules for Companies.

 

For further information:

 

 Alliance Pharma plc                                                       + 44 (0)1249 466966
 Cora McCallum, Head of Investor Relations & Corporate Communications      + 44 (0)1249 705168
 ir@allianceph.com (mailto:ir@allianceph.com)

 Buchanan                                                                  + 44 (0)20 7466 5000
 Mark Court / Sophie Wills
 alliancepharma@buchanan.uk.com (mailto:alliancepharma@buchanan.uk.com)

 Deutsche Numis (Nominated Adviser and Joint Broker)                       + 44 (0)20 7260 1000
 Freddie Barnfield / Duncan Monteith / Sher Shah

 Investec Bank plc (Joint Broker)                                          + 44 (0)20 7597 5970
 Patrick Robb / Maria Gomez de Olea

 

About Alliance

 

Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our
purpose is to empower people to make a positive difference to their health and
wellbeing by making our trusted and proven brands available around the world.

We deliver organic growth through investing in our priority brands and
channels, in related innovation, and through selective geographic expansion to
increase the reach of our brands. Periodically, we may look to enhance our
organic growth through selective, complementary acquisitions.

Headquartered in the UK, the Group employs around 285 people based in
locations across Europe, North America, and the Asia Pacific region. By
outsourcing our manufacturing and logistics we remain asset-light and focused
on maximising the value we can bring, both to our stakeholders and to our
brands.

For more information on Alliance, please visit our
website: www.alliancepharmaceuticals.com
(http://www.alliancepharmaceuticals.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOATIMPTMTJMBAI